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SUMMARY 
The aim of this project was to develop a novel method for typing urinary 
glycosaminoglycans (GAG) patterns to diagnose mucopolysaccharidosis (MPS). 
Measurement of total urinary GAG concentration was done by an automated 
dimethylene-blue (DMB) method on a centrifugal analyzer. Specific degrading 
enzymes were used to digest GAG present in the urine sample. After incubation with 
one specific enzyme, a decrease in total GAG concentration indicated the presence of 
the substrate for that enzyme. 
Adapting from a method developed by a previous student (Ngai, 1996)，it was found 
that the GAG-DMB reaction behaved differently in aqueous and urine matrices. With 
the present method, reaction time , had been extended from 40 to 60 seconds. The 
between-batch precision coefficient of variation was better than 7.52%. The linearity 
was up to 80mg/L with recovery of 99% and detection limit of 1.3mg/L. Correlation 
study using 70 patient samples showed that the previous method was 28% lower than 
the present one. Based on regression analysis, the age-related reference range was 
recalculated. 
Three GAG enzymes had been studied: chondroitinase ACII (CSE), chondroitinase B 
(DSE) and heparitinase (HSE). Both CSE and DSE degraded GAG in urine matrix, 
but less efficient than the activity in aqueous buffers. Unfortunately HSE from 2 
suppliers was not active and could not be used for further studies. Both CSE and DSE 
were specific in degrading their corresponding substrates. Their activities were not 
affected by the presence of other GAG. 25 U/ml of CSE digested lOOmg/L of 
chondroitin sulphate (CS) in urine within 1 hour while 0.05 U/ml of CSE w^s optimal 
to digest the same amount of CS within 24 hours. Similarly, 0.5 U/ml was the optimal 
amount of DSE for degrading lOOmg/L of dermatin sulphate (DS). Both CSE and 
DSE were stable at 4°C for a month after reconstitution. 
The novel method had been used to type the urinary GAG patterns in 3 MPS patients: 
2 confirmed cases of MPS type III and one case of suspected MPS type I/I W W I I . 
CSE and DSE did not change GAG concentrations in type III patient urine as the 
samples were not expected to contain these 2 GAG. For the unconfirmed MPS 
sample, DSE decreased the total GAG by 29% and CSE did not show any change. 
In conclusion, this novel method has a good potential to be used for MPS typing. It is 
simple, fast and reproducible. However, more studies are required before it can be 
introduced to the routine laboratory. 
Abbreviations used : 
AB Alcian blue 
BSA Bovine serum albumin 
C4S Chondroitin -4- sulphate 
C6S Chondroitin -6- sulphate 
CPC Cetylpyridinum chloride 
CS Chondroitin sulphate 
CSA Chondroitin sulphate A 
CSC Chondroitin sulphate C 
CSE Chondroitinase ACII 
DSE Chondroitinase B 
DW Deionized water 
GAG Glycosaminoglycans 
H Heparin 
HA Hyaluronic acid 
HC1 Hydrochloric acid 
HPLC High performance liquid chromatography 
HS Heparan sulphate 
HSEI Heparitinase I 
HSE HI Heparinase III 
KS Keratan sulphate 
LiCl Lithium chloride 
MPS Mucopolysaccharidosis > 
TLC Thin layer chromatography 
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The mucopolysaccharidosis (MPS) is a group of inherited disorders characterized 
chemically by excessive secretion of glycosaminoglycans (GAG) in urine. This is 
caused by deficiency of one of the lysosomal enzymes needed for stepwise 
degradation of GAG molecules (Stone et al, 1994). Undegraded GAG molecules will 
be stored in lysosomes and their accumulation results in dysfunction of cells, tissues 
or organs. GAG are released from the connective tissue into the blood stream and then 
excreted in urine. Urinary GAG level is elevated and the type of GAG present varied 
from different types of MPS. There are basically six types of MPS namely type I — 
type VII. The type of GAG involved are heparan sulphate (HS), chondroitin sulphate 
(CS) dermatan sulphate (DS) and keratan sulphate (KS) (Stone et al, 1994). 
Screening methods for MPS are based on the qualitative or quantitative measurement 
of excess urine GAG excretion. Conventional methods include spot tests, 
precipitation test, and determination of uronic acid (Pennock, 1976) These tests are 
not sensitive and include tedious steps rendering them not a good choice as screening 
test for routine laboratory. Automated dye-binding methods are better screening 
methods to ensure quick and reliable results. Spot urine instead of 24-hour urine can 
be used without sanq)le preparation. The dimethylene blue (DMB) dye-binding 
method has been reported free from protein and haemoglobin interference in the urine 
(Jone et a/,1992). A former MSc student in the Department has developed an 
automated DMB method with established local age-related reference range (Ngai, 
1994). 
Abnormally high GAG urine samples have to be typed according tov its GAG 
con^)osition. Thus, reliable and efficient qualitative analysis of GAG pattern is also 
important in the routine laboratory. One-dimensional or two-dimensional 
electrophoresis and thin layer chromatography are commonly used (Pennock, 1976). 
These methods are time-consuming and tedious. High performance liquid 
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chromatography (HPLC) can also be used (Hansen et al, 1997). However, this 
method requires expertise for interpretation and expensive instrumentation. 
Specific hydrolytic enzymes for GAG have been isolated from bacterial sources 
(Ernst et al9 1995). These enzymes are used for the study of proteoglycans and 
glycoproteins (Fransson et al, 1990). For example, heparitinase m (HSE ID) or 
heparitinase I (HSE I) can be used to digest HS; chondroitinase B (DSE) to digest DS, 
condroitinase ACT (CSE) to digest CS and keratinase to digest KS. The use of 
hydrolytic enzymes for the digestion of urinary GAG was reported prior to the 
analysis on HPLC (Hansen et a, 1997; Kodama et al, 1986). 
This project is to develop a novel method for efficient and reliable GAG typing that 
can be used in a routine clinicaLlaboratory. For a urine sample with elevated total 
GAG concentration, a specific hydrolytic enzyme (e.g. DSE) can be used to digest the 
corresponding GAG (e.g. DS) in the urine. This can lead to a significant decrease in 
the urine total GAG concentration if the corresponding GAG is present in a 
significant amount. However, if the corresponding GAG is not the principle molecule 
causing the abnormality, the urine total GAG concentration will remain unaffected. 
The change in total GAG can be accurately measured by the automated DMB method. 
By using a combination of specific enzymes, all the common GAG molecules in the 
urine sample can be deduced. Main efforts are focused on the adaptation of the DMB 
method to a different automated chemistry analyzer avattable in the laboratory. 
Optimal reaction conditions for hydrolytic GAG enzymes have to be established in 
the urine matrix. The new method will be correlated with conventional 
electrophoresis typing method using MPS patient samples. 
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2. LITERATURE REVIEW 
2.1 Causes and clinical syndromes in MPS 
2.1.1 MPS 
The MPS is a group of inherited lysosomal storage disorders of connective tissue. 
Each type of MPS has distinctive phenotypes and a progressive course due to a severe 
deficiency of an enzyme which catalyses a step in the degradation of GAG. It depends 
on the enzyme deficiency, the catabolism ofDS, HS, or KS may be blocked, singly or 
in combination; CS may also be involved (Dean et al9 1971). Lysosomal 
accumulation of GAG molecule^ finally results in dysfunction of cells, tissues, and 
organs. GAG fragments generated by different pathways are excreted in the urine. 
There are 10 known enzyme deficiencies that give rise to six distinct MPS. The 
stepwise degradation of GAG requires four glycosidases, five sulfatases and one non-
hydrolytic transferase (Benson & Fensom^ 1982). The disorders are chronic and 
progressive, often display a wide spectrum of clinical severity within one enzyme 
deficiency. MPS is transmitted in an autosomal recessive manner, except that of MPS 
II, which is X-linked. (Benson & Fensom, 1982; Blau et al, 1996). 
The different types of MPS share similarity in clinical features, though in variable 
extent of severity, involving facial abnormalities, organomegaly, bone deformaties, 
and dysostosis multiplex. Besides, vision, hearing, cardiovascular function and joint 
mobility may be affected. Profound mental retardation could be found in MPS I H, 
which is Hurler's syndrome, the severe form of MPS II，Hunter's syndrome, and all 
subtypes of the MPS HI, which is the Sanfilippo syndrome, but normal intelligence 
remained in other types of MPS. The bony lesions are specific for MPS IV (Blau et 
a/，1996), which is Morquio syndrome, are specific to that disorder. Defects 
associated with DS plus HS or KS storage produce striking skeletal changes, HS 
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storage is associated with mental retardation, and DS accumulation may lead to corneal 
clouding (Pennock，1973). 
The classical symptoms of coarse face，joint contractures, stato-motor retardation, corneal 
clouding, and skeletal dysplasia, are not specific features for MPS, may also be found in 
case of glycoproteinoses. There is a nonnal early development for about 6-12 months, 
followed by developmental delay and physical changes which are apparent by the end of 
the 1 year in the severe forms but not until early childhood in the milder forms. 
Behavioral problems related to CNS involvement may be present in the severe forms. A 
specific metabolic diagnosis is important in regard to prognosis and genetic counseling 
(Benson & Fensom^ 1982). 
2.1.2 Classification of MPS 
2.1.2.1 MPS I (Hurler's syndrome) 
Hurler's disease is the most severe of the MPS (Dean et al, 1971). Infants appear normal 
at birth. Patients with this condition are usually in infancy and early childhood with 
progressive deterioration of mental and physical ability associated with distinctive facial 
features. Corneal clouding, dea&ess, enlarged protruding tongue and open mouth are 
peculiar features of the patient. The neck is short，abdomen is protuberant and inguinal 
and umbilical hernia is common. Hepatosplenomegaly are seen from about 6 months of 
age. These children reach a learning plateau before the age of 2 years and death from 
cardiac failure or respiratory problems before the age of 10 years (Benson & Fensom^ 
1982). ^ 
i •‘ 
This disease is due to severe deficiency of the enzyme a-L-iduronidase, which is required 
for the degradation of DS and HS. As a result both types of GAG will be accumulated in 
the tissues with the lysosomes in the ratio of about 7:3 (Benson & Fenson^ 1982). 
Metachromatic granules in-the peripheral blood lymphocytes can be seen. The definitive 
diagnosis is the demonstration of severe deficiency of iduronidase in cultured fibroblasts, ^ 
leucocytes or serum. 
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2 1 1 2 MPS IS (Scheie syndrome) 
m s 'is a milder variant of iduronidase deficiency than Hurler disease. It is rarely 
diagnosed before the age of 6 years. Its major clinical features are coarse but not 
Hurler-like fecial features, corneal clouding and joint contractures, notably of the 
fingers. THe patients are of normal height and intelligence. Conq)lications include 
retinopathy, glaucoma, the carpal tunnel syndrome and hernias (Dean 过 al, 1971). 
The condition is due to the deficiency of a-L-iduronidase resulting in excessive 
urinary excretion of DS and HS. The diagnosis is confirmed by demonstrating severe 
deficiency of a-L-iduronidase in leucocytes. 
2 1 2 3 MPS II (Hunter's disease) 
彻 patients have protuberant abaomen with hepatosplenomegaly. S t r e s s of the 
joints occurs with the typical claw-hand deformity. Besides, there is marked 
hypertrichosis, growth retardation occurs so that the patients become severely 
dwarfed. Mental retardation is slow progressing and commonly associated wrth 
deafoess. Most patients develop osteoarthritis of the hips in later life, and death ！s 
usually due to cardiac failure associated withpulmonary hypertension (Holton, 1994). 
彻 biochemical deficiency of iduronate sulphatase results in excessive excretion of 
D S and HS, usually in equal quantities, sometimes HS predominates (Benson & 
F e n s o m , 1982). Specific diagnosis is established by demonstrating a severe 




2.1.2.4 MPS Type HI (The Sanfilippo diseases) 
There is severe mental defect with mild somatic or skeletal involvement, somewhat 
coarse feces, no gibbus, and absent or very light corneal clouding. Affected children 
become hyperactive, irritable, aggressive, and destructive. There is wide variation in 
the age of onset of the disease (Benson & Fensom, 1982; Kamp, 1979). 
.-jp 
The Sanfilippo diseases are due to the deficiency of lysosomal enzymes required for 
the complete exclusive degradation of HS and heparin, giving rise to Sanfilippo A, B， 
C and D. Patients with heparan sulphaturia are highly suspected of having Sanfilippo 
disease, and are readily diagnosed by enzyme assay (Emery & Rimoiij 1990). 
2.1.2.5 MPS Type IV (Morquio's disease) 
The peculiar features of MPS type IV are severe skeletal deformity (including 
dwarfism), corneal clouding and aortic valve disease. Patients excrete excessive 
amount of KS early in childhood although excretion pattern reverts to normal in 
adulthood (Holton, 1994). 
The enzyme defects in Type IVA is galactosamine -6-sulphatase deficiency whereas 
in type IVB is p-galactosidase deficiency. The definitive diagnosis is by 
demonstrating the deficiency of enzymes in cultured fibroblasts (Benson & Fensom^ 
1982). 
2.1.2.6 MPS Type VI (Maroteaux - Lamy syndrome) f 
Patients show skeletal changes with normal intellect, and dwarfism is extremely 
marked. Hepatosplenomegaly, cardiac abnormalities and hernias are common. 
Excessive excretion of DS is observed (Pennock, 1973). The simplest method of 
diagnosis is the demonstration of arylsulphatase B deficiency in leucocytes or 
cultured fibroblasts (Benson & Fensom^ 1985). , 
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2 1 2 7 MPS Type VH (Sly syndrome) 
Tins a rare type of MPS with diversity in the clinical presentation. Excessive 
excretion of urinary CS was reported ( B e _ & 权 脚 恥 侧 ) . C i r c u l a t i n g 
o o c y t e s have metachromatic inclusions in most, not all. Hence, diagnosis . made 
b y showing the deficiency of enzyme P-glucuronidase in leucocytes or fibroblasts 




2.1.3 Treatment and prospects for MPS 
In general the treatment is to manage the many handicaps and disabilities arise from 
the disease, and to correct the metabolic defects (Blau et al, 1996). 
2.1.3.1 To manage the handicaps and disabilities 
Respiratory infection ,, 
Respiratory infection is treated with the use of antibiotics. Obstructive airways disease 
is common and responds well to treatment with bronchodHator drugs such as 
salbutamol, ephedrine. 
Cardiac failure 
Cardiac failure may respond to Oiuretics such as frusemide. Patient with valvular 
cardiac failure may respond to digoxin but with poor prognosis (Masuda et al, 1993). 
Ocular disease 
The ocular disease is treated by corneal transplantation or by reinfiltration of the 
cornea. The corneal transplantation may have difficulty during anaesthesia, because of 
obstruction of airways and patients should undergo full assessment and management 
of a cardiovascular and respiratory dysfunction. Reinfiltration of the cornea can give 
patients a period of useful vision (Blau et al, 1996). This treatment is to overcome 
severe corneal clouding in MPS WIS and in other types of MPS (Benson & FensoriL， 
1982). 
2.1.3.2 Enzyme replacement 
Fratantoni et al (1968) stated that the defect in GAG metabolism could be corrected in 
cultured fibroblasts from patients with either MPS IH or MPS H suggested the 
possibility that this could be achieved in patients (Spranger,1990). Di Ferrante et al 
(1971) used repeated infusion of frozen plasma or white cells for the treatment of 
Hurler's and Hunter's diseases. The treatment induced increased degradation of acid 
mucopolysaccharides leading to clinical improvement. Enzyme replacement before ^ 
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the onset of regression appeared to be a reasonable possibility (Blau et al, 1996). 
Nevertheless, it needs further investigation to ensure this approach of treatment is 
promising. The actual difficulties are that the blood brain barrier: the plasma enzymes 
pass poorly into the CSF. In addition, the lysosomal enzymes have short half-lives, 
which means frequent daily administration of the enzyme would be necessary 
(Spranger, 1990). , 
2.1.3.3 Bone marrow transplantation 
This treatment has successfully reversed the clinical and biochemical features of MPS 
ffl. But the patients have to fece the problems of graft versus-host disease and other 
complications of bone marrow transplantation (Shapiro et al9 1995; Fmaizumi & 
Gushi, 1994). Enzyme provided by cells of donor bone marrow can reduce the storage 
of GAG in somatic tissues, but high risk and uncertain long -term neurologic outcome 







2.2 Basic aspects of GAG 
2.2.1 Distributions of GAG 
The majority of GAG in the body are linked to core proteins forming proteoglycans 
(also called mucopolysaccharides). The GAG extends perpendicularly from the core 
in a brush-like structure. The linkage of GAG to the protein core involves a specific 
trisaccharide conqjosed of two galactose residues and a xylulose residue (GAG-
GalGAlXyl-0-CH2-protein). GAG molecules are O-linked to serine through a linkage 
sequence at its reducing end (Ernst e/ al, 1995). 
GAG molecules are not uniformly distributed in the body, but vary in their distribution 
according to the type of tissue (Table 2). For example, it appears that arterial walls of 
both large and small vessels contain a greater variety of GAG types than do the skeletal 
material such as cartilage and bone. In some instances the polysaccharide chains lie in 
• , 
the cell surfeces (Kennedy, 1979). It also has different amounts present in different 
locations in the same tissues (Bjelle 1975; Waterson & Wessler, 1971). Furthermore, the 
quantitative level is an age-dependent function (Roden & Horowitz^ 1978). 
f 
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Chrondroit in4-sulphate 2-5 0.1-1.3 Cartilage, bone, 
(C4S) ^ 他如血 
Chrondroitin~6-sulphate 2-5 0.1-1.3 Heart valve, 
(C6S) 咖 帕 
Dermatan sulphate ( D S ) 2 - 5 1.0-3 Skin, heart, valve 
I tendon, arterial 
wall 
Hyaluronic acid (HA) 1-5 0 Differe， 
I connective tissues, 
I skin vitreous 
I humour, synovial 
I fluid, umbilical 
I cord, cartilage 
Heparin (HP) 1-2 1.6-3 Lung, Hver, skin, 
I mast cells 
Keratan sulphate ( K S ) 0 . 5 - 2 • 0.9-1.8 C o n ^ cartUage, 
I intervertebral disc 
Heparan sulphate ( H S ) " " " " 0 . 4 - 2 Lung, arterial wall, 
I r cell surface, 
I kidney, liver 




2.2.2 Functions and Roles of GAG 
Molecules of GAG are located primarily on the surface of cells or in the extra-cellular 
matrix. Along with the high viscosity of GAG comes low compressibility, such as 
hyaluronic acid, which makes these molecules ideal for a lubricating fluid for joints. In 
addition, their rigidity provides structural integrity to cells and provides passageways 
between cells, allowing for cell migration. They modify the structural properties of 
connective tissue, particularly the fibrillar elements of collagen and elastin (Devlin, 
1992). 
GAG influences cellular metabolism by trapping water and excludes large molecules 
from cartilage. They have important roles to act as anticoagulant and antilipaemic such 
as heparin. In addition, DS is also anti-thrombotic and has a lipaemia clearing action 
(Blau et al, 1996). GAG has been shown to inhibit calcium oxalate stone growth and 
aggregation, though the effect of nucleation still remains unsettled (Thome & Resnick， 
1984). 
2.2.3 Stepwise degradation of GAGs 
Initially GAG is broken off from its complex with protein by a proteolytic enzyme. 
Then a stepwise release of monosaccharide molecules by the sequential action of 
sulfatases, glucuronidases, galactosidases, iduronidases and other clearing enzymes at 
the non-reducing end of the GAG chain in the lysosome. In MPS, degradation continues 
until a point is reached when a linkage cannot be cleaved because of a deficient enzyme. 
The GAG present in the tissues and in the urine is the result of the action of later 
enzyme (Ernst et al, 1995). 
2.2.4 Source of urinary GAG 
The exact origin of urinary GAG is not elucidated in sufficient details. It is believed that 
they are released into the lumen of the tubules during normal turnover of kidney cells but 
at least in part they are derived from the blood stream (Blau et al, 1996). The GAG 
excreted in urine is not exactly the same as they occur in the tissue. In s 
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tissues, GAG molecules are present as very high molecular weight proteoglycans. 
GAG aggregates in urine are only low molecular weight polymers (8,000-12000 Da) 
(Ernst et al, 1995). During the release from the connective tissue into the blood stream 
and excretion in urine, these polymers might have undergone some modifications of 
the chemical structures (Ernest et al, 1995; Hansen, 1997)，either as a result of 
depolymerization or desulphation or both. Urinary GAG molecules are the final 
degradation products from proteoglycans (Ernst et al, 1995). 
The relative concentration of low molecular weight GAG (<3000 Da) is higher in 
MPS than in normal individuals. These fragments represent 50% of the total GAG in 
the urine of MPS I patients and only 10% in normal urine (Blau et al, 1996). 
Furthermore, in normal urine, GAG is either free (20-30%) or bound with 
glycoproteins (70-80%) and the percentage fraction bound to glycoproteins is age-
dependent (Kao et al, 1967). The most abundant GAG excreted are C4S and C6S. 
Some of the HS may also originate from the renal tissue. In renal insufficiency, a 
decreased in glomerular filtration causes the retention of GAG in plasma and 
increases urinary GAG concentration. In addition, connective tissue disorders lead to 
an increase in plasma GAG, accompanied by a corresponding elevation in urine 
(Friman et al, 1977). 
2.2.5 Common features of GAGS 
GAG are polymers of repeated disaccharide units consisting of an uronic acid and a 
hexosamine. The uronic acid is either glucuronate or iduronate whereas the 
hexosamine is either N-acetylgalactqsamine or N-acetylglucosamine. Bibsynthesis of 
all GAG, except hyaluronic acid is initiated from a core protein. They are long 
unbranched polysaccharides now referred to as acid GAG that exists in tissue linked 




GAG is highly negatively charge biopolymers, due to the presence ofuronic acids in 
the backbone and the extensive sulfation. The chemical composition of GAG from 
various tissues differs highly. The individual chains in a GAG preparation have 
different molecular weights and compositions. GAG chains from the same tissue, 
which are linked to different core protein, may have differences (Shum, 1993). 
Structurally, the ubiquitous GAG is made up of repeating units of uronic acid (L-
iduronic acid or D-glucoronic acid) and a hexosamine (D-glucosamine or D-
galactosamine) connected by pi-3 and p 1-4 linkages, except in Keratan sulphate, D-
galactose replaced the uronic aci^. Most of the GAG is sulphated except hyaluronic 
acid (Hensen et al, 1997). 
2.2.6 Factors affecting the excretion pattern of GAG 
The excretion of GAG in urine is not only depending on pathological, but also by 
• ... 
physiological factors such as age, sex, temperature, pregnancy and physical exercise 
(Newton D.J. et al, 1979). In normal urine the most abundant GAG excreted are C4S 
ands C6S, HS may also be found (Hansen et al, 1997). 
Sex 
Male excretes more GAG in the urine than female (Newton et a!, 1979). 
彻 f 
In infants and children they excrete more GAG than adults do, hence age-dependent 
reference range is necessary to justify if a person has elevated level of urinary GAG. 
The excretion correlates with the body surface area and depends on age (Roden & 
Horowitz, 1978), The excretion pattern not only differs quantitatively but also varies 
qualitatively according to—age (Newton et al, 1979). The percentage of C6S excreted 
remains high till the age of 10 years but decreases with the advance of age, whereas 
C4S increases to a maximum at 40 years of age (Holton, 1994). Children with 
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classical Morquio's disease before the age of 10 years have an excess of urinary KS 
and CS, but in older patients KS excretion may be within normal limits (Benson & 
Fensom, 1982). 
Orcadian rhythm 
The excretion of GAG has a wide daily variation and is influenced by circadian 
rhythm. CS and HS excretion in normal subjects show a marked peak at 1800-2200 
hours (Newton et al，1979). 
Pregnancy 
The total GAG excretion increases during pregnancy from the antepartum levels and 
this increase persists in the postpartum periods. Besides, infections in obstetric and 
gynaecological patients cause an increase in GAG excretion (Thompson & Ledger， 
1974). 
Surgical stress • 
A large ten^)orary increase in the nondialyZable polyuronides will occur in surgical ‘ 
stress. Patients excrete more GAG after major surgical procedures such as 
gastrectomy, intestinal resection, cholecystectomy, thyroidectomy and heriorrhaphy 
and arthrotomy ( Rigillo et a/,1969). 
Physical exercise 
Strenuous exercises increase the excretion of GAG. The reason may be due to the 
metabolism of a fundamental substance of connective tissue (Rigillo et al’ 1969). 
f 
These changes are mediated through the effect of the endocrine system on connective 
tissue conq)onents. 
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2.3 Methods for MPS Diagnosis 
2.3.1 Qualitative urine methods for screening and typing 
2.3.1.1 Spot tests 
Spot tests are screening methods based on the interaction of urinary GAG with a 
suitable cationic dye. They are simple and easy and no urine preparation is required. 
A fixed volume of urine is applied to filter paper, dried, and stained with a solution of 
suitable dye such as toluidine blue (Berry & Spinanger，1960)，alcian blue (Carson & 
Neill, 1962) or azur A( Berman et al, 1971). This technique is still used in some 
laboratories in Hong Kong as a screening test for MPS, disregard the fact that none of 
these tests takes into account of the urine concentration and age-related changes in 
GAG excretion. False negative results are common. 
2.3.1.2 Precipitation methods 
GAG reacts with quaternary ammonium compounds to give a precipitate which can 
be used as a screening test (Scott, 1960). A semi-quantitative test using 
cetylpyridinium chloride (CPC) was described (Manley & Hawksworth 1966). CPC 
was added to urine and the turbidity recorded by a nephelometer measured at 680 nm. 
False positive or false negative results may obtain if the ionic strength, pH and 
concentration of CPC was not properly controlled (Pennock, 1973). 
2.3.1.3 One-dimensional electrophoresis 
The one-dimensional electrophoresis using agarose gel or cellulose acetate allows the 
separation of all known animal GAG (including two subclasses of HS，CS, DS，HA, 
heparin and KS). The principle of the method is by placing the gel in an electric field 
with a discontinuity. Different GAG molecules are then selectively resolved by 
combining their migration properties in a barium acetate buffer and their differential 
sensitivity to precipitation by ethanol (Cappelletti et al，1979; Furderburgh & 
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Chardler, 1978). This typing method is suitable for routine screening of large 
numbers of samples (Hopwood, 1982). 
2.3.1.4 Two-dimensional electrophoresis 
The electrophoretic separation of urinary GAG was carried out by using two different 
buffer systems: 0,1M pyridine / 0.47M formic acid buffer at pH 3 and 0.1M barium 
acetate at pH 8 on a cellulose acetate membrane (Hata & Yutaka^ 1972). Urinary 
GAG is first purified from the urine matrix by CPC precipitation. Separation of 
different types of GAG is performed by two consecutive runs in two directions with 
standards included. The GAG is separated according to the sulphate component in 
the first run, whereas in the second run, GAG are separated with reference to the 
polypeptide backbone (Hata & Yutaki 1972; Krisko & Wilson^ 1974). 
2.3.1.5 Thin layer chromatography 
The method developed by Humbel and Chamoles (1972) is based on the differences 
in solubility of the calcium salts of GAG in different concentrations of alcohol. The 
# 
thin layer plate is chromatographed through six separate solutions of decreasing 
concentrations of alcohol (70%, 50%, 40%, 30%，20%, 10% ethanol). After the 
chromatography is completed, the plate is dried and stained for 10 minutes in a 1-% 
alcian blue in 70% ethanolic-acetic acid mixture. Excessive stain is removed by 10% 
acetic acid. The solutions used must be freshly prepared. Interpretation is easier than 
electrophoresis, despite the fact that running procedure is tedious and time-
consuming (Pennock, 1976; Lippiello & Mankin^ 1971). 
f 
2.3.2 Quantitative methods for urinary GAG 
2.3.2.1 Measurement ofhexuronic acid 
All GAG, except KS, contains hexuronic acid which reacts with carbazole in the 
presence of concentrated sulphuric acid to give a magenta coloured product. In order 
to separate the GAG from other hexuronic acid-containing metabolites, CPC 1 
precipitation (Thompson & Castor 1966) is done prior to quantitation or dialysed 
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samples (Segni et al 1964) are used. This method cannot measure KS. Precipitation 
is required and takes about a whole day. Furthermore considerable amount of GAG 
may be lost in the process of precipitation or dialysis. 
2.3.2.2 HPLC or Column chromatogr^hy 
The GAG can be separated by high performance liquid chromatography (HPLC) on a 
hydroxyapatite column after enzymic digestion, with GAG molecules labelled with a 
fluorescent reagent, 2-aminopyridine (Kodama et al, 1986). The binding property of 
each type of GAG with hydroxyapatite is different depending on the sulfate content 
and molecular weight. The method facilitates rapid separation of GAG, especially DS 
and CS (Hansen et al，1997). HPLC held an important place in research into GAG 
excretion patterns but is time consuming and results in a large number of fractions for 
further analysis, therefore unsuitable for routine laboratory screening or classification 
ofMPS. 
2.3.2.3 Dye-binding methods 
The Alcian blue method . 
In 1973，Whiteman described a method using the dye alcian blue (AB) for 
quantitative determination of GAG isolated from urine (Stone et al, 1994). AB reacts 
with GAG to form insoluble complex under controlled conditions of pH and 
electrolyte concentrations. The insoluble complexes formed, a very fine precipitate, is 
washed with ethanol so as to redissolve in sodium dodecyl sulphate to form a clear 
blue solution. The absorbance of the solution is directly related to the concentration 
of GAG present. This method is superior than the spot test and precipitation method 
in that it takes into consideration the urine creatinine concentration. They are widely 
used as screening test for MPS. But some loss of the precipitate in the process of 
removal of the supernatant is inevitable; hence the GAG may be underestimated 
(Pennock, 1976; Jong, 1994). 
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1,9 dimethylmethylene blue method 
The basic dye 1,9-dimethylmethylene blue (DMB)，first studied by Taylor and Jefifree 
has been used to assay sulphated GAG in cartilage tissue cultures. The assay has been 
adapted for the qualitative determination of total sulphated GAG precipitated from urine 
by Panin et al More recently, Whitely et al (1989) and De Jong et al (1994) have 
developed simple spectrophotometry methods for the direct quantitation of urinary 
GAG. GAG concentration is determined by reaction of the dye with the urine sample. 
The change in absorbance, either due to the increase in GAG-DMB convex or a 
decrease in the DMB concentration, m proportion^ to the GAG concentration in the 
sample. This is a quite sensitive method in determining the concentration of GAG, by 
means of the buffer used, the a i a y is not affected by the protein and haemoglobin 
present in the m n e (Jong et al, 1992). No sample pretreatment is required and results 
can be available within minutes. This renders the DMB as a choice for routine screening 
f o r MPS, It gradually replaces the CPC and alcian blue method m some laboratories, 
233 Cytatagical studies 
Investigation of the staining properties and the ultrastrueture of lymphocytes and 
cultured fibroblasts has been rewarding both from the point of view of diagnosis and 
research into the aetiology of the genetic I ^ S , In the blood of the affected MPS 
individuals 18-39% of lymphocytes contain metachromatic granules (Alder-Reilly 
bodies) which are best demonstrated with toluidine blue O at pH2 (Blau et at, 1995). 
f 
2.3.4 Tissue culture 
Danes & Beam (1965) showed that skin ftooblast cultures of patients suffering from 
Hurler's syndrome contained increased numbers of metachromatic granules. Increased 
concentration of DS was also found in such culture media. 
� 
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2.3.5 Tissue biopsy 
Tissue biopsy such as skin biopsy and conjunctiva biopsy may aid to diagnose 
difficult cases. Tissues should be examined histochemically and where fecilities are 
available with the electron microscope. This study may combine with the tissue 
culture method. In cutaneous biopsy,-large cells distended with storage material, 
called "balloon" or Hurler cells in the subcutaneous tissues can be seen (Blau et al9 
1982). 
2.3.6 Prenatal diagnosis of the MPS 
This is usually done at the fourteenth week of pregnancy, either in supernatal fluid 
where the concentration of acid^MPS is approximately four times normal or by a 
study of cells cultured from amniotic fluid. It should be noted that there are other 
conditions with elevated level of GAG in the amniotic fluid rendering the diagnosis 
difficult (Fensom & Bens叫 1994). Other techniques include enzyme assays of fetal 
cells, tissues or fluids. In MPS IDC, in which diagnosis of the affected fetuses was 
confirmed by demonstration of low enzyme activity in extracts prepared from 
chorionic villi. In MPS E, which is sex-linked, the mother may be shown to be carrier 
before she has given birth to an affected child. Female carriers of the X-linked gene 




2.4 Bacterial GAG hydrolytic enzymes 
GAG degrading enzymes have been used in the studying of GAG structure and 
mechanisms of GAG activity. These enzymes are specific for certain sequences of 
GAG chain (Densai et al 1993; Fransson et al, 1990). The action of the hydrolytic 
enzymes were indicated in figure 1. The substrate specificity of GAG degrading 
enzymes often have formed the basis for interpretation of composition and structure 
of GAG chains (Nader et al, 1979 & 1987; Linhardt et al 1990; Habuchi et al 1992.). 
Heparin hydrolase, keratanase, hyaluronic acid hydrolase and various exoglycosidases 
are involved (Hopwood, 1989). These GAG enzymes are mainly of bacterial origin 
and are classified into three categories such as heparinases, chondroitimses and 
hyaluronidases (Linhardt et al9 1990). These lyases 6ave been purified and utilized 
mainly for analytical and industrial applications. The lyases degrade GAG by means 
of eliminative cleavage whereas the hydrolases degrade GAG by hydrolytic cleavage 
(Ernst et al, 1995). The main difference is that in the eliminative mechanism, the C5 
h y d rogen of uronic acid is abstracted, forming an unsaturated C4-C5 bond. Whereas 
in the hydrolytic mechanism, a proton is donated to the glycosidic bond, breaking the 
glycosidic oxygen and creating an 05 oxonium ion followed by water addition. This 
neutralizes the oxonium ion and saturates all carbons (Linhardt et al, 1990). The 
lyases can only cleave linkages on the non-reducing side of uronic acids. On the other 
hand, the hydrolases can be specific of the two bonds in the repeat dissacharides 
(Ernst et al, 1995). These enzymes are commonly used to investigate the biochemistry 
of GAG and its physiological implications (Densai et al, 1993). 
f 
The sequential application of the GAG specific enzymes has recently been reported to 
study urinary GAG compositions in patients with Graves eye disease (Hansen et ah 
1997). CSE was used for the digestion of chondroitin sulphate A and C，chondroitin 
ABC lyase for the degradation of DS, and hyaluranate lyase for the reaction with HA. 
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After enzymatic digestion, the resulting degradation product was analyzed by HPLC. 
The structural information and GAG concentration can be determined. The method 
was shown to be a reliable test system for the detection and quantification of GAG 
conponents, with overall recovery rate and sensitivities superior to the other 





2.5 Summary, of Literature Review 
There are many methods used to screen for MPS, among those methods mentioned 
above, the spot test give high incidence of false-negative results (Pennock，1976). 
The method used to measure uronic acid fail to detect MPS IV. It was found that 
automated dye-binding method using DMB is superior than other methods. The 
reason is that spot urine with no sample^recipitaion (Jong et al9 1989) is required and 
result can be obtained within minutes. Besides, the reaction is not affected by 
haemoglobin and protein up to concentration of5g/L (Jong et al，1992). 
For typing of urine samples with abnormal GAG concentrations, qualitative analysis 
by electrophoresis or TLC (Pemiock，1976) are time consuming. Urine sample 
preparation prior to is necessary incurring lost of GAG. Separation of KS from CS 
was poor by using barium sulphate to run electrophoresis, this render the 
identification of GAG excretion pattern difficult. 
The enzymatic degradation method of GAG by eliminative and hydrolytic enzyme 
could be used as a new attempt to type the excretion pattern of urinary GAG in MPS 
patient. The successful application in the study of GAG pattern in urine samples of 
Graves opthalmopathy patients is a supportive evidence (Hansen et al, 1997). Instead 
of using the expensive HPLC equipment, other simple methods of detecting the 
change in GAG pattern might be possible. 
f 
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3. AIMS OF STUDY 
A quick and reliable method is necessary to screen and type urinary GAG patterns for 
detection ofMPS in routine laboratory. The aim of this project is to develop a novel 
method for typing urinary GAG patterns using specific GAG degrading enzymes. 
This can be achieved by: 
1. To adapt an established automated DMB dye-binding method on the Cobas 
Fara automatic centrifiigal analyzer; 
2 . To set up an one-dimensional electrophoresis method for the separation of 
specific urinary GAG; 
3. To establish optimal conditions for enzymatic degradation of specific urinary 
GAG; 
4. To correlate the enzymatic method with the electrophoresis method; and 
5. To apply the novel method in studying MPS patient sauries. 
f 
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4. MATERIALS AND METHODS 
4.1 Sample collection 
Spot urine samples for this project w^re collected from routine Chemical Pathology 
Laboratory at the Queen Elizabeth hospital. Three patient samples, 2 confirmed cases 
of MPS type in and 1 suspected case of MPS type I/IWIA/II, were kindly supplied 
by the Department of Chemical Pathology at the Princess Margaret Hospital. 
4.2 Materials & Equipment 
Formic acid sodium salt, tris (hydroxymethyl) aminomethane (Tris), CS sodium salt, 
DS sodium salt, HS sodium salt, KS sodium salt, hexadecytri-methylammonium 
Bromide, cetylpyridium chloride (1 -Hexadecylpyridinium chloride), alcian blue 8GX， 
lithium chloride, barium acetate, glacial acetic acid, bovine serum albumin, sodium 
acetate and heparinase m (from Flavobacterium heparinum) were purchased from 
Sigma (St. Louis, MO, USA). DMB was bought from Aldrich Chemical Company 
(Milwaukee, WI, USA). Chondroitinase ACE Arthro (from Arthobacter aurescens), 
chondroitinase B (from Flavobacterium heparinum), and heparitinase I (from 
Flavobacterium heparinum) were purchased from Seikagaku Corporation (Tokyo, 
Japan). 
Cobas Bio and Cobas Fara used for the automated DMB method were from Roche 
(Basele, Switzerland). Electrophoreis was performed by the Beckman Paragon system 
(Beckman Instruments, Irvin, CA, USA). f 
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4.3 Preparation of Reagents and Standards 
4.3.1 Stock DMB reagent solutions 
Solution A was prepared by dissolving 34.8mg DMB in 5ml 95% ethanol. 
Solution B，0.055M sodium formate, w^s prepared by adding 3.74g sodium formate and 
2ml formic acid to a final volume of 1 L with deionised water (DW). 
Solution C was prepared by mixing 5ml solution A with 995ml solution B. 
Solution D9 2M Tris buffer, was prepared by dissolving 242.2g Tris to a final volume of 
lLwithDW. " 
4.3.2 Working DMB solution 
Freshly prepared working DMB solution (DMB 30umol/L，Tris buffer 0.2mol/L, 
pH8.8) was prepared by mixing 5.5ml solution B, 3.5ml of solution C and lml of 
solution D. ‘ 
4.3.3 GAG standards 
HS, DS, KS and CS stock standards of2000mg/L were prepared by dissolving 20mg of 
the corresponding salts in 10ml DW respectively. GAG working standards were 
prepared by diluting appropriate volumes of the respective stock solution in DW. 
4.3.4 Reagents for electrophoresis 
f 
4.3.4.1 0.1M barium acetate solution 
This was prepared by dissolving 25.54g of barium acetate in 800ml DW and the pH was 
adjusted to pH 5.0 using glacial acetic acid. The volume was made up to 1 L with DW. 
27 
4.3.4.2 15% ethanolic barium acetate 
This was prepared by mixing 15ml absolute ethanol with 85 ml 0.1M barium acetate 
solution. 
4.3.4.4 Alcian blue working solution 
This was prepared by dissolving 0.5 g Alcian blue to 500ml 4% acetic acid solution. 
；-M 
4.3.4.5 O.lMTris Buffer 
This was prepared by dissolving 1.49g Trisma Preset (pH 7.6) in 100ml DW, adjust 
pHto7.0withHCl. 
4.3.4.6 CTB-Tris solution 
This was prepared by dissolving O.lg CTB in 100ml of 0.1M Tris buffer. 
4.3.4.7 2.0 M Lithium chloride 
This was prepared by dissolving 8.5 g LiCl in 100ml DW. 
4.3.5 Reagents for enzymatic degradation 
4.3.5.1 Reconstitution of CSE enzyme 
2.0 M acetate buffer was prepared by dissolving 15.5g anhydrous sodium acetate with 
0.63 ml acetic acid and make up to 100 ml with DW containing 0.5% BSA. The pH 
was adjusted to 6.0. Lyophilised CSE was supplied in 5 units per vial. CSE working 
solutions were prepared by reconstitution with the 0.02M acetate buffer. 
f 
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4.3.5.2 Reconstitution of DSE enzyme 
0.25M Tris HC1 buffer was prepared by dissolving 3.03g Tris HC1,1.3lg NaCl, 0.22g 
CaC12 and 0.05g BSA in 100ml DW. The pH was adjusted to 8.0 at 30 °C by 1 M 
HCl. Lyophilised DSE was supplied in 0.1 unit per vial. DSE working solutions were 
prepared by reconstitution with 0.05M Tris HCl buffer. 
4.3.5.3 Reconstitution of HSE I enzyme 
0.1M acetate buffer was prepared by dissolving 1.66g CaCl2 with 100ml 0.1M sodium 
acetate buffer. The pH was adjusted to 7.0 at 37�C. Lyophilised HSE I was supplied 
in o.l unit per vial. HSE I working solutions were prepared by reconstitution with 
0.05M acetate buffer. 
Table 2 summarizes the different parameters for the specific GAG degrading enzymes 




[ E ^ ^ T c s i DSE pHSE 
Origin Arthobacter Flavobacterium Flavobacterium 
Aurescens heparinum heparinum 
U n c i a l TT ^ “""" 0 1 
Action of enzyme EUminative Eliminative Eliminative 
cleavage cleavage cleavage 
Substrate CSA and CSC "DS HS 
r g ^ ： TrisHCL& TrisHCL buffer Ca acetate buffer 
“ 丁 7 _ _ 
Optimal temp ° C 37 30 3 7 
Optimal pH U 0 8 0 7 0 
Activators Ca++CO-H-Mg-H- ~ “ C a + + B A + + 
Ba++ 
Inhibitors Pb++Cu++Fe++Fe++Ba++ 
Sn++ DS C0++P04- EDTAS04--
Table 2 Enzymes and substrates used in the study 
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4.4 Methods 
4.4.1 Cobas Bio DMB method 
The programming of Cobas Bio (Ngai, 1996) was as shown on Table 3. 
4.4.2 Cobas Fara DMB method 
The programming of Cobas Fara was as shown on Table 4. The DMB dye in buffer 
was pipetted into the cuvette rotor and the initial absorbance of the dye was recorded. 
After incubation for 10 seconds, the urine samples were pipetted into the cuvette 
rotor. Decrease in absorbance at 593 nm started in seconds and the final absorbance 
taken at 60 seconds. The change in absorbance was due to the decrease in the dye 
concentration. The absorbance was read against a reagent blank and was calculated to 
correlate the concentration from the calibration curve. 
4.4.3 Evaluation of methods 
4.4.3.1 To study the matrix effect 
The reaction of DMB with GAG standards in aqueous and urine matrice was studied. 
An aqueous CS standard solution containing 50mg/Lof CS was prepared by dilution 
of the CS stock standard solution with DW. A urine sample containing 50 mg/L of 
total GAG was used for the DMB reaction. The changes in absorbance were studied 
on both the Cobas Bio and Cobas Fara for a period of 4 minutes. 
4.4.3.2 Calibration 
The calibration curve was prepared by using CS working standards. The 
concentrations of standards were 10，20，30，40，60，80 mg/L respectively. The 
standard curve was plotted as the decrease in absorbance versus that of the total CS 
concentrations. 
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I 1. U n i t s ~ ~ “ ^ “ ~ 
2. Calculation factor 1 
3. Standard 1 concentration 20 
4. Standard 2 concentration 4 0 
5. Standard 3 concentration ‘ 8 0 
6. Limit 0 
7. Temperature (° C) 2 5 
8. Type of analysis 1 
9. Wavelength (nm) 5 9 3 
10. Sample volume (^ 1) 2 0 
11. Diluent volume (JJ.1) ^ 0 
12. Reagent volume (pi) 2 5 0 
13. Incubation time (seconds) 1 0 
14. Start reagent volume (^ 1) 0 
15. Time of first reading (seconds) 0.5 
16. Time interval (seconds) . 4 0 
17. Number of readings 2 
18. Blanking mode 0 
19. Printout mode 1 
l _ * 




__V T C n AT ANALYSIS 
GENERAL R 1 Reagent 1 : 250 uL 
, . Time control : No 
Measurement mode : Absoibance ！ ！ncubation : 10 s 
Reaction mode .: Rl-I-S-A j^j : 5 s 
Calibration mode : Linear regressioii M : No 
Reagent blank : No blank s Sample volume: 20 uL 
Wavelength ： 593nm Diluent name : H20 
Temperature : 2 5 ° C volume 10 uL 
Decimal position : 1 • Cleaner cycle : OFF 
Unit : mg/L Time control : NO 
A Readings 
Fkst ： 0.5s 
Number ： 3 
Interval ： 40s 
M ： NO 
M : NO 
CALCULATION : C d i b i a t i 0 Q 
« , u ur . vrn Calibration intervfel : On request 
Sample check limit : NO ^ N u m b e r of standards : 6 
Reaction d i rec t s ： g r e a s e S 二 溫 : 2 
Co^rsionFactor : 1.0 ， • ： 。 广 ( 球 ) 2 � 20.0 
Test range Low ： NO , : N 0 L 1U U 
Range type : Nonnal range 3 0 0 4: 40.0 
Normal range Low : NO High • NO 3. 州” 
Number of steps : 1 6 0 0 6: 80.0 
Calculation step A : Endpoint First • M 1 ) . 一 
Last : 3 Replicate: Delicate 
Deviation: 5.0% 
Correction STD: NO 
CONTROL REACTIONMODE 
Control interval ： On request N a m e : Glycosaminoglycans 
. . _ Rl Reagent 
Monthly report : ON x Mcubation 
r x i Pos • NO S S a m p l e , ！ i l ‘ wn A Measurement cycle 漂 = ： { J o Rl Dimethylene blue reagent 




concentrations in these samples, prepared by pooling different normal urine specimens, 
were 7 mg/L, 40mg/L and 70 mg/L respectively. To measure the between-batch 
precision performance, 3 urine samples were aliquoted and stored frozen at -70 °C. 
Each time when the automated DMB method was run on Cobas Fara, one set of the 
aliquoted samples were thawed and assayed together with other samples. 
4.4.3.4 Linearity check 
A "blank" urine sample containing 7mg/L of GAG was spiked with CS standard of 
2000mg/L. Urine samples containing CS ranging from 0.2mg/L to lOOmg/L were 
prepared by diluting the CS stock standard solution with the ''blank" urine. GAG 
concentration in each sample was measured in duplicates by the DMB method on Cobas 
Fara as previously described to check the linearity of the assay over the calibration 
range. 
4.4.3.5 Detection Limit 
Detection limit was determined by assaying 30 water san^les. The mean plus 3SD of 
absorbance difference at 593 nm (AA) value Was calculated and the corresponding lowest 




4.4.3.6 Recovery study 
Four urine samples were prepared to contain different amounts of CS according to 
T a b l e 5. The total GAG concentration in each tube was measured in triplicates by the 
automated DMB method on Cobas Fara. The % recovery was calculated according to 
standard definition. 
.-•jr 
Urine Volume of 50ul of stock CS Distilled 
Sample Sample Standard Water 
(ul) (mg^) (ul) 
_ - - 50 
S+100 950 2000 0 
S+50 « 0 1000 0 
S+25 950 500 0 
Table 5 Urine sample preparation for recovery study 
4.4.3.7 Correlation with Cobas Bio to develop the reference range 
T h e total GAG concentrations in 70 random urine samples were measured by Cobas 
Fara in parallel with Cobas Bio. The measurement protocols was on Tables 3 and 4 
(Ngai 1996). The results were plotted and linear regression analysis with Deming 
correction was performed. The resulting regression equation was used to recalculate 
the age-related reference range established by the previous MSc student on Cobas Bio 
(Ngai, 1996). ^ 
, ‘ 
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4.4.4 Electrophoresis method 
4.4.4.1 Sanq>le preparation 
Precipitation of GAG from the urine sample is required before electrophoresis. Hii$ is 
to remove interference from the staining of GAG after the separation. Both the CTB-
Tris reagent and urine samples were warmed to 37 °C in a water bath. Urinary 
precipitates, if any, were removed by centrifugation. Equal volumes of CTB-citrate 
and urine were mixed. The mixtures were allowed to stand for 30 minutes aX 37 °C 
(or place at room temperature overnight), and then centrifuged at 3500 rpm for 15 
minutes. The supernatant was decanted and the GAG was in the pellet. The pellet was 
redissolved by the addition of 150 uL 2M LiCl and vortexed for 1 minutes. GAG was 
then precipitated once more by the addition of 800ul absolute alcohol and vortexed 
for 10 seconds. The turbid mixture was transferred to microtube and centrifuged at 
10000 rpm for 5 minutes. lOul saline was added tq dissolve the GAG pellet and 
vortexed. The mixture was centrifuged at lOOOOrpm for 2 minutes and the supernatant 
was ready for use in electrophoresis. 
4.4.4.2 Electrophoresis procedure 
Five microliters of the purified GAG sample were applied onto the agarose 
electrophoresis gel and the sample was allowed to equilibrate with the gel for 15 
minutes. With the barium acetate buffer, the gel was subjected to a constant voltage 
of 50V for 10 minutes. The gel was removed from the Paragon and immersed into a 
tray containing 15% ethanol in barium acetate buffer for 3 minutes. The gel was then 
washed with the barium acetate buffer for 3 minutes. The gel was blotted dry and 
placed back into the electrophoresis apparatus was then run in the same buffer 
solution at 50V for 25 minutes. The gel was then placed in a cold cell with cold buffer 
and subjected to a further electrophoretic run at 50V for 25 minutes, Tl^ gel was 
taken out and inimersed in the 50% ethanolic barium acetate buffer tank for 3 
minjates. The gel was washed by barium acetate buffer and then blotted dry. The gel 
was re-lun in buffer at 50 V for 20 minutes, then a cold cell with cold buffer at 100V 
it 
36 
for 10 minutes. The gel was stained with alcian blue for 30 minutes and then 
destained with acetic acid to remove background. 
4.4.5 Enzymatic degradation method 
4.4.5.1 Digestion of GAG in aqueous and urine matrix 
An aqueous CS working solution of lOOmg/L was prepared by appropriate dilution of 
the CS stock standard solution with E)W. A urine sample containing approximately 
lOOmg/L of CS was also prepared by spiking CS stock standard solution into a pooled 
urine sample that had a measurable GAG of 7 mg/L. A set of 4 tubes was set up 
according to Table 6. The reaction mixture was kept in the Cobas Fara reaction tube 
and incubated at 37°C for 24 hours. The total GAG concentration in the tubes was 
measured by the automated DMB method on Cobas Fara at 0，1，14 and 22 hours. 
The experiment was repeated using DS for DSE and HS for HSE respectively. The 
measurement of GAG concentration was performed at 0，1，2, 16 and 25 hrs. At the 
end of the incubation period, all the remaining samples were subjected to the one-
dimensional electrophoresis to show whether GAG in the sample had been degraded 
by the enzymes. 
f 
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： j u r i ^ 1 Enzyme 丨 Buffer | DW Spiked STD 
ofGAG 
B f f i " " " " " m H "20id 80ul 20ul 
B ^ k 2 " 2 8 0 ^ m i " " — 80ul 2 Q u l 
A ^ _ 2 0 u l » 2 0 u l 
STD 
Urine spiked"280ul 2 0 u l 
with STD _ J _ _ _ _ J _ 
Table 6 Composition ofreaction tubes for the study ofGAG digestion in aqueous 
and urine matrice by enzyme 
4.4.5.2 To optimize the amount of enzyme used to degrade GAG 
Different concentrations of CSE were used to digest CS in order to find out the 
minimal amount of CSE required to completely digest CS within 24 hours. Enzyme 
solutions ranging from O.OlU/ml to 2.5U/nil were prepared by serial dilution. To 
determine the minimal amount of enzyme that can be used to degrade lOOmg/L of CS 
in 280ul of urine in 24 hrs, a series of CSE concentration was prepared by serial 
dilution of the CSE stock solution with the CSE buffer. Eight reaction tubes were set 
u p as shown in Table 7. The reaction tubes were incubated at 37�C water bath for 24 
hr. Thereafter, total GAG concentration in each reaction tube was measured by the 
automated DMB method on Cobas Fara. The experiment was also repeated for DSE 
using DS spiked in urine. f 
38 
Enzyme Urine Enzyme B u f f e r ~ S p i k e d G A G 
concentration STD 
used in this 
study — 
2.5U/ml 280ul 編 80ul 20ul 
lU/ml _ 280ul "20d BOul 20ul 
Q,5U/ml 一 280ul "20u1 80ul 20ul _ 
Q,25U/ml j O ^ 80ul 20ul _ 
Q.lU/ml 280ul 2Qul BOul 2Qd 
Q.Q5U/ml 280ul 80ul 20ul __ 
0.025U/ml 280ul 20ul 80ul 20ul 
Q.QlU/ml 280ul 20ul 80ul 20ul 
T a b l e 7 Composition of reaction tubes for the optimization on the amount of 
enzymes used for GAG degradation 
4.4.5.3 To study the specificity of GAG degrading enzyme 
To study the substrate specificity of CSE, a series of 8 reaction tubes were set up as 
shown on table 8. The reaction tube DS-B containing 280ul of a urine sample 
containing lOOmg/L of DS without CSE. The reaction tube DS-B had the similar 
composition of DS-B with the addition of 5U/ml CSE. The other 3 pairs of reaction , 
tubes contained different GAG molecules. These reaction tubes were incubated at 
37�C for 24 hrs. Total GAG concentration in each reaction tube was measured at 
0,1,22 and 24 hrs. This experiment was also repeated using 0.5U/ml of DSE. 
1 Urine Enzyme Buffer " " " D W " " Spiked 
STD of 
GAG 
D S . E 2R0ul 20ul 80ul ^ 20ulDS 
— C S ^ B k ^ 2 8 M 2 0 u l _ _ 
C S ^ 9.R0ii1 20ul 80ul . 20ulCS 
- H S ^ B k ^ 2 8 M ? 0 u l _ _ 
HS-E 沙 Qui 20ul 80ul 2 0 u l H S 
^ K S ^ " B t e ^ 2 8 M m _ _ 8 0 u l 2 0 u l _ _ 2 0 u l K S ^ 
KS-E 280u! 20ul 80ul 2 Q u l K S 
Table 8 Composition of reaction tubes to study the specificity of GAG ， 
degrading enzymes 
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4.4.5.4 To study the interaction of GAG 
A series of 6 reaction tubes were set up to study whether different GAG had an 
inhibitory action on CSE as shown on table 9. The CS+DS blank tube had 280ul of 
urine containing 50mg /L of CS and 50mg/L DS, without CSE. Hie CS+DS tube had 
the same composition as the CS+DS blank tube containing 5U/ml of CSE. The 
reaction tubes were incubated at 37°C for 24hrs. Total GAG concentration in each 
tube was measured 5 times for 0-4hrs and 3 times for 20-24 hrs. This experiment was 
similarly repeated using 0.5U/ml of DSE. 
r f U r i ^ I Enzyme I B u f f e r [ D W I Sp&ed � STD of 
. GAG 
CS+DS B 減 280ul " m i " 8 ^ 1 ； 二 • 
CS+DS _ " 2 8 M " " " " m i " 8 0 S 二 S I “ 
CS+HS B l a r i c _ ；二•"“ 
CS+HS p M - 2 0 ^ - ¾ " IQulCS 
CS+KS B l a n k p M m l ^ 2 0 u l 二 g 一 
CS4-KS p w " " " p i " " " " " 8 M 
J L 
Table 9 Composition of reaction tubes for the study of interaction amongst 
GAG and the degrading enzymes 
4 4 5 5 To study the stability of enzyme CSE and DSE 
The stability of CSE stock solution at 4°C was studied for a period of 1 month. 20ul 
of a freshly prepared CSE stock solution w明 added to 2?Dul of a urine containing 
lOOmng/L of CS in a reaction tube. The reaction tube was incubated at 37�C for 24 
hrs. Total GAG concentration in the tube was measured by tte automated DMB 
method on Cobas Fara at 0,1,2,15 and 24 _ TQie CSE stock soh^A was kept at 4 
oC for 30 days. The above experiment w ^ t h ^ ^ p e a t e d . The stability ofDSE stock , 
• . , 
solution at 4°C was similarly studied for a p&aod of I morith.,， 
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4.4.5.6 Study ofMPS patient san^le 
The total urinary GAG concentration in a MPS patient sample was first measured by 
the automated DMB method on Cobas Fara. If the total GAG concentration was 
greater than 100mg/L，the sample would be diluted to about lOOmg/L using DW. 
280ul of the sample was added to each of the 3 reaction tubes containing 20 \il of 
either CSE, DSE kor HSE. The reaction tubes were incubated at 37°C for 24 hrs. 
After the incubation, total GAG concentration in each tube was measured by Cobas 
Fara. The decrease in GAG concentration in the reaction tube containing the GAG 
specific enzyme (e.g. DSE) indicated that the urine sample contained that 
concentration of GAG ( e.g. DS). 
Three patient san^les had been meaSUred by this novel enzymatic typing methods: 2 
cases of confirmed MPS m and one case of suspected MPS type I/H/VI/Vn. 





5.1 Performance characteristics of the DMB method 
5.1.1 Matrix effect 
It was found that DMB-CS reaction was complete in aqueous solution within 30 
seconds. But the reaction took 60 seconds to complete in urine matrix on both Cobas 
Bio and Cobas Fara. The reaction curve of the DMB-CS reaction on Cobas Fara in 
both matrices were shown in Figures 2 and 3, respectively. Thus, the reaction time 
was extended to 60 seconds for the rest of the project. 
5.L2 Calibration 
The standard curve was plotted as the decrease in absorbance versus that of the total 
GAG concentration (Figure 4). The curve was linear up to 80mg/L. A linear 
relationship (r=0.999) was observed between the absorbance change and the CS 
standard concentrations. For urine sample with measured GAG concentration 
exceeded 80mg/L, they were diluted with DW. 
• i 
5.7.5 Precision performance 
Tables 10 and 11 showed the results of within-run and between- run imprecision of 
the Cobas Fara DMB method at different concentration of urinary imprecison. The 
within-run coefficient of variation (CV) varied from 1.76—7.15 % and the between-
run CV varied from 2.13- 7.52 %. 
5.1.4 Linearity Range f 
The linearity range was at least 4 and 80 mg/L as shown on Figure 5. 
5.1.5 Detection limit 
The detection limit was found to be 1.3 mg/L. 
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Figure 3 urine reaction curve ,T, 
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~ “ 7mg/L ' 40mg/L 70n^/L “ 
Number "20 20 ^ 0 ' 
Mean T H 40.39 73.3 一 
(mg/L) -
S.D. 0.51 L43 1.29 
(mg/L) -
C.V. 7.15 3.55 1.76 
(%) L 
Table 10 Within-batch precision performance for the DMB method 
oil Cobas Fara 
40mg/L 70mg/L 一 
Number ‘ 2 0 2 0 ~ 20 
• t. 
M e a n : 13 41.64 71.12 
(nig/L) 
S.D. 0.55 1.98 1.51 
( 球 ) 
C.V. 7.52 4.76 2.13 
J 
Table 11 Between-batch precision performance for the DMB method 






































































































Table 12 showed that the mean recovery of 3 different concentrations of GAG 
ranging from 90.2-109.9%. 
i_ t -
CS added (mg/L) Mean recovery (%) 
' 25 902 ‘ 
5 0 ^ “ ； 97J 
100 ^ 1 0 9 . 9 
_ 丨 丨 丨 • . 丨 ， • • • • • _ _ • “ • I k • . I • . . . 
Table 12 Recovery performance of the DMB method on Cobas Fara 
5*L 7 Correlation of Cobas Fara with Cabas Bio 
Figure 6 showed the correlation erf Cobas Fara with Cobas Bio. The linear regression 
equation after Deming correction was [ Cobas Fara ] ^ 1.28 * [Coba Bio ] + 2.513. 
Based on iim regression equation, the adjusted age-related reference range for HK 
Chinese was shown on Table 13. 









0-5months ~ 26.3-69.6 
6-12monthi 二‘ 20.3-309 
13-23 months "“ 19.9-26.7 
2-3 years 1&7-26.1 
I — 
4-5 years 13.6-25.3 
6-7 years ~ 11.9-20.5 
8-9 years ~ 7 11.8-17.3 
10-14 years “ 4.9-13.9 
1^-19 years “ 2.5-7.1 
>20 years 1.7-6.3 ^ — — — — 









































































































































































































5.2 Results of GAG enzVmatic degradation 
5.2.1 Enzymatic degraddtion of GAG in aqueous and urine matrix 
The degradation ofCS by CSE in aqueous and urine matrices was shown on figures 7. 
Similarly, the degtadation ofD^ by DSE was shown on figure 8‘ However, the HSE 
did not have any effect on HS even in the aqueous matrix, indicating that the enzyme 
was not active. The percentage change of GAG over the incubation period was 
summarized on Table 14. It appeared that the enzyme was more efficient in the 
aqueous matrix than the urine matrix. 
Figures 9，10 and 11 showed the electrophoresis pattern of GAG present in the 
diffei-fettt reaction tubes containing'the aqueous GAG standards. It clearly showed that 
both CSE and DSE degraded the corresponding substrate while HSE did not. 
• * 
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Enzyme [ . ~ Substrate %degradation in % degradation in 
aqueous matrix urine matrix 
^SE""""‘ "DS 84 72 
"CSE ""CS 9 9 J 95 
"HSEI BS ; T 5 ^ 
j^ tm 14 Results ofG^iG enzymatic degradation in aqueous and urine matrices 
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The result of enzymatic degradation correlate with electrophoresis 
CS digested by CSE 
‘ mmmnm _ 巧 
‘ ’ ‘、： ：‘'-、：' '、。： “ p , . … 、 ‘ 
.�:::、':• ‘ ‘‘� 邮S 
CS CS CS 
Figure 9 +CSE 
enzyme 
Track 5 and Track 7 were CS standard without enzymatic degradation 
Track 6 was CS standard with enzymatic degradation by CSE. 
5^ 
.二. • ； > •‘•*： - f : ' . : ， . … ^ - . - CZ :.<V:- • � ; - v v ? ' ' - ^ V - . • *v ,v'v". v ^ ‘ 
->:、、二：乂 ‘ 二 乂;:-':7 二 “ 
. . : 1 . . : ¾ . 、 確 ^ ( � C . � , : ••'�” . ‘ . : • 、 , ） ' : � v � . ； 心 . ' . . : . . - • : ' .、.；二 
.> - - 二’“ ‘ ^ " 一 广 r ' � ^； .^ ； -.：‘' -.‘‘ 
‘；；二>〜'》•、 • „ … . . j K ^； ：； N > 、 ‘一-'.V , r , ‘ �.�.’XV：- '’D'. \ ?/、；-• 、/?(,•-，',： -；-：1 、 r ， - , . '、 
- > • " . • , r ^ - ' ^ - v .、: ？:•-、',。.々 :..;:〜••,:''/ >.:•..•:.，:..:.： ‘ ^ C :,X'一;• •_•:'’,々 :•，...••"•： :. , ..i) 
.•... • V - ？> - - ‘ v ' c t :•，-»:；. ‘ ' . , . : � , y , . . .,.?、•；•‘�— �� , ••• • - � v,v 
� v ' v V ' . - . - v {‘ : • � * ' � -- •» f ； ？ . 广‘“/ 〜、、‘‘，，�x I' ‘ “ 云"‘;々 ‘y  ‘ ‘ ,:、、’•’广�’.I '、 :"、，’ “，、. Z • / «； 'Z ’ ‘ ‘ “ - , ‘ ，二 ，’ M , •"、，-'r ；y - . ：.!«#. ：'^ . ^  n.' -*•',•、、<、, 一； .f . ” ". 、?-. v / ； ； :'•'、./, >':)‘••.，‘ .： 
‘ •；、二、丄：：，):'•》、. ’：  二彡 „ 1 ‘  * ，’.二二、. :、 '".>. - ‘ , 
-•、、、:'  ‘ 、。-.,,•: “,、“、省‘、‘、，、.‘.> 二、“ ,、 * ‘、 二 , ：: ’ 
…/：：:'、： ¥ I � . •一 ；‘' “ 、 ： “ ' ' ' - 4 
w � ‘ ： 二: • � . v、：’ ’：. / 
. : : : 、 ； - - ¾ ¾ ^ • 二“： •�’ - - v ； * - ‘ ' 
“ ： ： ； 兮 ： 、 - 、 “ , ： 、 , , . - 二 - . 、 ’：.一 ？“ •、： ： •'•？二饿？、"- ‘： 
DS DS DS DS DS 
+DSE+DSE 
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Figure 10 Electrophoresis result of the digestion of DS by DSE enzyme 
Track 1,2 and 6 were DS standard without DSE digestion. 
Track 7 and 8 were DS standard with DSE digestion. 
f 
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The result of enzymatic degradation correlate with electrophoresis 
HS digested by HSE III enzyme 
二 1 . : .靉^^¾ 
.BECKMAN Paragon® SPE Gel • 
.喜 . . : 1 ^ : . 
.餘E.,.姆. 
* 1 Z 3 4 S<h 7 8 9 10 * 
轟：褲:寶A • 
Figure 11 
Track 5 : HS standard with HSE enzyme digestion 
Track 6 : HS standard without HSE digestion. 
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5.2.2 To optimise the amount of enzyme for GAG degradation 
The results of CS degradation by different amounts of CSE were shown in Figures 12 
and 13, respectively. 0.05U/ml was the minimal concentration of CSE required to 
con^letely digest 100 mg/L of CS in a 280-pl urine sample within 24hrs. On the 
other hand，0.5U/ml of DSE was the minimal concentration required for the same 
amount of DS in 24 hrs. 
5.2.3 The specificity of GAG degrading enzymes 
The specificity of CSE against HS? DS and KS was shown on Figure 14. It was 
observed that CSE only degrade CS and did not degrade other GAG. DSE was also 
specific and did not degrade GAG other than DS. 
5.2.4 The interaction of GAG 
The degradation of CS by CSE in the presence of other GAG was shown on Figure 
15. CSE activity was not inhibited by the presence of DS，HS and KS. This was also 
true for DSE without any inhibition of the enzymatic activity by CS, HS and KS. 
5.2.5 The stability of enzymes 
The degradation of CS by freshly reconstituted CSE and CSE stored at 4 °C over 1 
month was shown on Figure 16. The enzymatic activity of fresh CSE and aged CSE 
was coir^arable. Both enzyme preparations digested CS completely withrn an hour. 
Similarly, DSE was still active after storage at 4 °C for 1 month as shown on Figure 
16. 
5.2.6 MPS patient stu^ f 
5.2.6.1 Typel/IIAT/Vn 
The degradation of the GAG in this MPS patient sample by CSE and DSE was shown 
on Figure 17. The percentage change of GAG over the incubation period was shown 
on Table 15. There was a 29% decrease in total GAG concentration after DSE 
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digestion indicating that DS was present in the urine sample. However, there was no 
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Digestion of CS by CSE 
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Figure 12 Optimal amount of enzyme for degradation of CS by CSE 
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5.2.6.2 MPS Type HI patient 1 
The result of the enzymatic degradation ofCS and DS by CSE and DSE in MPS type 
HI patient was shown on Figure 18.The percentage change of GAG after enzyme 
digestion was shown on table 15. There was no decrease in total GAG concentration 
after CSE and DSE digestion, indicating the absence of both CS and DS in the 
sample. 
5.2.6.3 MPS Type HIC patient 2 
The result of the enzymatic degradation ofCSE and DSE was shown on Figure 19. 
The percentage change of GAG after degradation was shown on table 15. There was 
no decrease in total GAG concentration after CSE and DSE digestion, indicating the 
absence of both CS and DS in the sample. 
MPS classification " " “ E n z y m e G A G ejqjected Total GAG 
% degradation 
Type I/II/VI/Vn "DSE DS，HS，CS 29 
CSE 0 
Typem CSE ~HS 0 
DSE 0 
Type HIC CSE ~HS 0 ^ 
DSE 6 
























































































































































































































































































































































































































































































































































































For the laboratory investigation of MPS, urine samples are first screened for the 
excessive GAG excretion. Once a urine sample is found to have increased GAG 
concentration, it is important to identify the presence of specific GAG pattern. There 
are 6 different types of MPS and the^urinary GAG pattern provides the guideline for 
studying the tissue GAG enzyme deficiency to confirm MPS typing. With the 
introduction of automated dye binding method, the reliability and efficiency of 
screening procedure becomes acceptable in routine clinical laboratory practice. 
However, the typing methods are still laborious, time consuming and unreliable. 
Large urine sample volume is needed as GAG purification is always required prior to 
either electrophoresis or thin-lay^er chromatography. The present typing method is not 
suitable in the routine laboratory. 
This is the first report on the development of a novel method to type urinary GAG 
pattern for the diagnosis of MPS. The method was based on an established automated 
quantitative DMB method for urinary GAG. Substrate specific GAG degradation 
enzymes were tested in urine matrix to digest the corresponding GAG. In the 
presence of one specific enzyme, the decrease in GAG concentration indicated the 
presence of the specific substrate of the enzyme. The amount of specific GAG can be 
measured by the DMB method without any urine sample purification. According to 
the results in this report, it is possible to complete both GAG screening and typing-
within 2 hours. 
i 
6.1 Automated DMB method on Cobas Fara 
Automated DMB method were developed since 1989 (de Jong et al, 1989; Whitley et 
al, 1989). It was further improved to eliminate the interference from hemoglobin and 
protein in the urine sample (de Jong et al, 1992). The principle of these methods is to 
measure the increase in absorbance due to the formation of GAG-DMB complexes at 
520 - 530 nm. It was reported that the different GAG molecules reacted with DMB 
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resulting in slightly different absorption maxima ranging from 524 -532 nm (Stone et 
al, 1994). Thus, the use of a single wavelength to measure the product leads to 
inaccuracy. The previous MSc student developed an alternative automated DMB 
method to measure the decrease in absorbance at 593 nm which is the absorption 
maxima for the DMB dye (Ngai, 1996). Such method overcomes the inaccuracy 
problem and allows the use of one single wavelength for measurement. 
The previous student developed the new automated DMB method on the Roche Cobas 
Bio automated centrifugal analyzer. This analyzer was not available in the laboratory 
where the novel typing method was to be developed. A similar analyzer from the 
same manufacturer, the Cobas Fara, was available. No major problem was expected 
to transfer the DMB method^ from Bio to Fara as both instruments use the same 
principle. The Fara was a later model with more sophisticated software programming. 
However, it was found that the GAG-DMB reaction behaved slightly differently in 
the aqueous and urine matrices, leading to further studies. 
The reaction between GAG and DMB completed in 30 seconds in aqueous matrix and 
the previous Cobas Bio method used 40 seconds for end point measurement (Ngai, 
1996). It was found that 50 seconds were required for complete GAG and DMB 
reaction in urine matrix. This phenomenon was observed on both instruments, 
indicating this was not due to instrument specific parameters. When 40 seconds was 
used for measuring urinary GAG on the Cobas Bio, a falsely low result should be 
obtained. The new Cobas Fara DMB method used a 60 seconds for end point 
measurement. The correlation study using 70 patient urine samples clearly showed 
that the Fara results were about 28% higher than the Bio results. De Jorfg reported the 
first automated DMB method that measured the absorbance 10 seconds after the urine 
samples mixed with the dye (Jong et al, 1989). However, he later reported an 
improved version that measured the absorbance 70 seconds after the mixing of urine 
samples and reagent (Jong et al, 1992). Although their reports did not explain the 
reasons for extending the reaction time, it would probably be due to the incomplete 
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reaction as reported. Another earlier DMB method reported that the absorbance 
measurement was done within 30 minutes (Whitley et al, 1989). 
With correlation study between the 2 instruments, a linear regression equation was 
established. The equation was used to recalculate the only Chinese age-related 
reference ranges for urinary GAG developed on Cobas Bio. It was noted that the 
sample size for each age group was small, application of these reference ranges to the 
general population need careful consideration. More data should be accumulated to 
set up the reference range in the future. 
The withiri-batch and between-batch CV of the Fara method were 1.76-7.15% and 
2.13-7.52% respectively. The precision performance was comparable to the Bio 
method (Ngai, 1996) which was within 7% for both parameters. Similarly, the CV 
stated by Panin (1986) were 1.6% to 2.5% and 1.8% to 4.5% for within and between-
batch precision, respectively. The recovery ranged from 90 to 110% which was 
acceptable and compared to that of 71% to 107% by Panin (1986). The linearity was 
at least 80mg/L and compared to 70mg/L of the method by Ngai (1996). As normal 
subject usually did not have concentration over the calibration range, it was sufficient 
for routine screening. For urine samples with GAG concentrations exceeded the 
linearity range, dilution with DW prior to analysis was necessary. The detection limit 
of this method was 1.3mg/L and was comparable to the automated method on Cobas 
Bio (Ngai, 1996) which was 0.8mg/L. As normal urine samples seldom contained 
GAG of very low values, therefore detection limit was not important in this study. 
In summary, this DMB method on Fara was efficient, accurate and ^ith analytical 
performance similar to published methods using DMB dye binding principle. This 
could be used as a MPS screening method for routine laboratory. No sample 
preparation was necessary and results could be obtained within minutes. 
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6.2 GAG specific degradation enzymes 
The key of this novel GAG typing method lies in the ability of the enzymes to be 
active in the urine matrix. This eUminates the tedious and time consuming steps of 
GAG purification that usually takes 2 days prior to electrophoresis or thin-layer 
chromatography. Thus, the first study was to show that the enzymes were active in 
the urine matrix. Control experiments were also required to measure the enzyme 
activities in.the aqueous buffers, indicating that the enzymes were active. 25U/ml 
CSE completely digested lOOmg/L CS which was spiked in aqueous buffer and urine 
matrices within 1 hour. This indicated that the CSE was active in urine matrix. 
Similarly, 0.5U/ml DSE digested lOOmg/L DS within 2 hours in aqueous and urine 
matrices. The enzymatic actions were confirmed by the electrophoresis results, where 
CS band was absent after CSE digestion; DS band was absent after DSE digestion. 
But it was found that enzymatic digestions was more efficient in the aqueous buffer 
than in the urine. 
Unfortunately, both HSE III and HSE I was not active and failed to digest HS in 
aqueous buffer or urine matrix. This was confirmed by the electrophoresis result 
where the HS band was still present after the HSE IE enzyme digestion. These 2 
enzymes were purchased from two separate companies in USA and Japan. It was 
suspected the enzymes were denatured during transportation as they were delivered 
via airmail at room temperature. The American company had replaced another lot of 
the enzyme, however, still unable to be useful in this project. Much of the time was 
wasted in proving the problem to the company and ordering from another Japanese 
source. Since the most prevalence type of MPS was type III (Van DefKamp, 1979) 
with an incidence of 1 in 24000，the ability to use HSE in this typing method is 
crucial. To solve this problem, the manufacturers might have to ship the enzymes in 
dry ice but this could be very expensive. 
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The enzymes were expensive and experiments were conducted to study the — 1 
amount of enzymes required to digest the GAG over a longer period of time - 24 
h o u r s Such a long period of incubation could still be acceptable to routine laboratory 
a s t h e enzyme incubation would not required any technician time. For CSE, 0.05U/ml 
o f enzyme was the optimal amount to degrade 働mg/L of CS within 24 hrs. Tins 
represented a 500-fold dilution of the stock CSE solution and can reduce the running 
cost substantially. However, further dilution of DSE stock solutbn could not degrade 
the DS completely in 24 hours. 
Specificity of the degrading enzyme was also important for this novel typing method. 
CSE was found to be specific for CS digestion and did not degrade DS, HS and KS. 
S i m i l a r l y DSE was specific for DS digestion and did not degrade CS, HS and KS. It 
has been reported that CSE was .gmflcantly inhibited by DS especially when the 
s a mples contamed extremely large amounts ofDS (Saito et al, 1968). In the study to 
i n v est l gate whether the presence of GAG rmxture would inhibit the activity of CSE, , 
w a s found that HS, DS and KS did not interfere with the enzymatic actmty of CSE. 
Similarly, DSE activity was not affected by the presence of other 3 GAG molecules. 
The GAG specific degradation enzymes were all delivered in lyophilised powder. 
They had to be reconstituted in worlang buffer prior to use. However, only a small 
volume of enzyme solution was required. In order not to waste the reconsUtuted 
enzyme stupes were conducted to study the storage stability of the reconsUtuted 
enzyme soluUons. Itwas found that both CSE and DSE were stable up to 1 month at 
4 oC T h i s w a s better than the manufacturer's claim that the enzyme was only stable 
f 0 r 1 week at 4 � C after reconstitution. The stability might also be improved when the 
enzyme solutions were kept at lower temperature； like - 7 0 � C Furthermore, the 
reconstituted enzymes might also be lyophilised again for opdmal storage condmon. 
嫂 T o test the validity of this novel typing method, patient sample study was essential. 
However, the prevalence of MPS was low and different types of MPS sample were 
71 
difficult to acquire. For the 2 MPS HI urine samples, both DSE and CSE did not 
change the total GAG concentration. This was expected as MPS HI p a i n t s only had 
elevated HS excretion. Unfortunately, HSE was not active and could not be used m 
the study For the unconfirmed case ofMPS Type I/II/WVII，29% decrease in total 
G A G was observed in the presence ofDSE, indicating the presence of DS in the urrne 
s a m ple CSE had no action on this urine sample, indicating that there was no CS in 
the urine DS was expected to be increased in Types I，II and VI； while CS could be 
present in excess for Type VIL Unfortunately, there was insuffiaent sample to be run 
in the electrophoresis. 
In summary, the results suggested that there was a great potential for further 
development of this novel typing method. With a large amount of enzymes, the 
degradation could be accomplished m an hour. This could lead to the development of 
the most efficient method for GAG typing. 
f 
72 
7. CONCLUSION & SUGGESTION FOR FUTURE STUDIES 
The Cobas Fara automated DMB method established in this project has improved the 
accuracy performance over the previous Cobas Bio method by taking into 
consideration of the GAG-DMB reaction in urine matrix. Together with the use of 
GAG-specific degrading enzymes, this project has demonstrated the potential of 
developing a novel method for tyt5ing urine GAG patterns to aid the diagnosis of 
MPS. This new typing method could be simple, fast and reproducible that are suitable 
to be used in routine clinical laboratory. Urine sample volume required for the 
method would be 1-2 ml, desirable for collection from infants. 
To further develop this novel urinary GAG typing method, it is important to identify a 
suitable source of HSE. MP—S III has been reported to be the most prevalent type 
amongst MPS patients (Van De Kamp, 1979), the ability to demonstrate the presence 
of HS is essential. Efforts could be made to discuss with the enzyme manufacturers to 
ship the enzyme under dry ice and this would increase the cost. It might also be 
possible to purify the enzyme locally. 
More efforts should also be spent to study the reaction conditions for the GAG-
specific degrading enzymes, especially factors that could affect enzyme activities in 
the urine matrix. It would be important to identify interfering factors like enzyme 
inhibitors. The pH, ionic strength and temperature used in this project have been 
adapted from the manufacturer's suggestion. Due to the limited time and resource, 
detailed optimisation of these reaction conditions had not been performed. These 
conditions, if optimised, might improve the enzymatic reaction in the urine matrix so 
that a smaller amount of enzyme could be used. Other sources of enzyme might be 
identified to improve the quality of the enzyme supplied. 
The prevalence of MPS in Hong Kong has not been properly studied. However, the 
experience in local • laboratories indicated that the prevalence is not high. The 
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frequency of requiring urinary GAG typing would be low. Since the enzymes are 
usually supplied in lyophilised powders, reconstituted enzyme solutions might be 
wasted if it could not be consumed in one single experiment. It would be beneficial to 
study the different methods of preserving the reconstituted enzyme solutions, for 
example storage at ultra-low temperatures, or lyophilisation of the reconstituted 
enzyme solutions. ‘ 
Due to the limited time period for this project and the difficulty of finding patient 
samples containing KS, degrading enzymes for KS had not been studied. Such an 
enzyme should be included as a profile for GAG typing for unknown patient samples. 
To investigate unknown samples, the proposed procedure is that urine samples would 
be screened by the DMB method to measure the total GAG concentration. The 
samples with GAG concentration above the age-related reference range would be 
subjected to the typing method by enzymatic degradation. More reference samples 
would be required to improve on the reliability of the age-related reference range. 
Furthermore, the typing method has the potential of providing age-related reference 
range for each individual GAG present in urine sample. 
The usefulness of this novel method could only be properly evaluated by measuring 
more samples from confirmed MPS patients. It would be difficult to collect samples 
locally as the prevalence appeared to be low. Collaboration with international MPS 
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